(Q54616855)

English

Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21274533

Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. (English)

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21274533

cerebrospinal fluid

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

Takeshi Masuda

1

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21274533

Noboru Hattori

2

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21274533

Akinobu Hamada

3

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21274533

Hiroshi Iwamoto

4

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21274533

Shinichiro Ohshimo

5

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21274533

Masashi Kanehara

6

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21274533

Nobuhisa Ishikawa

7

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21274533

Kazunori Fujitaka

8

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21274533

Yoshinori Haruta

9

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21274533

Hiroshi Murai

10

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21274533

Nobuoki Kohno

11

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21274533

publication date

28 January 2011

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21274533

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21274533

67

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21274533

6

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21274533

1465-1469

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21274533

https://scigraph.springernature.com/pub.10.1007/s00280-011-1555-6

0 references

Leptomeningeal metastases from solid malignancy: a review

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1555-6

21 January 2018

Leptomeningeal carcinomatosis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1555-6

21 January 2018

Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1555-6

21 January 2018

Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1555-6

21 January 2018

Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1555-6

21 January 2018

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1555-6

21 January 2018

Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1555-6

21 January 2018

Gefitinib is also active for carcinomatous meningitis in NSCLC.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1555-6

21 January 2018

High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1555-6

21 January 2018

Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1555-6

21 January 2018

Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1555-6

21 January 2018

A case of radiation recall pneumonitis induced by erlotinib, which can be related to high plasma concentration

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1555-6

21 January 2018

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1555-6

21 January 2018

Single-dose clinical pharmacokinetic studies of gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1555-6

21 January 2018

Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1555-6

21 January 2018

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1555-6

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1555-6

21 January 2018

Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1555-6

21 January 2018

Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1555-6

21 January 2018

Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1555-6

21 January 2018

Identifiers

10.1007/S00280-011-1555-6

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21274533

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21274533

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54616855&oldid=1245641984"